Innate Pharma to participate in the Evercore ISI 4th Annual Healthconx Virtual Conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...
Innate Pharma Third Quarter 2021 Report
Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca’s randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical...
Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting
The companies will present pre-clinical data on Innate’s lead ANKET TM asset, IPH6101/ SAR443579, the first NKp46/CD16-based NK cell engager targeting CD123 These data highlight molecule’s favorable...
Innate Pharma announces Conference Call and Webcast for Q3 2021 Business Update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, November 16, 2021, at 2 p.m. CET / 8 a.m...
Innate Pharma 2022 Financial Calendar
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar: March 24, 2022: Publication of 2021 financial statements May 10, 2022...
Number of shares and voting rights of Innate Pharma as of October 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...
Number of shares and voting rights of Innate Pharma as of September 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...
Monalizumab data from COAST trial presented at ESMO Congress 2021
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial...
Innate Pharma Reports First Half 2021 Financial Results and Business Update
First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre...